News › Clinical Practice, Industry News, Patient Care

Botox and the Breast

December 16, 2016

Botulinum toxin type A plays a role in inhibiting one of the most serious breast surgery complications, capsular contracture. It does so through the TGF-β/Smad signaling pathway, according to a new study.
Researchers treated cultured human fibroblasts in vitro with TGF-β1 and/or botulinum toxin type A. Then they looked at collagen, matris metalloproteinase and Smad expression, according to the abstract.
They found that botulinum toxin type A treatment inhibited Smad 2 phosphorylation and expression of collagen types 1 and 3. But the same treatment enhanced matrix metalloproteinase-2 and matrix metalloproteinase-9. They found that, in vivo, treatment with the neurotoxin reduced capsule thickness and Smad2 phosphorylation in silicone-induced capsules, according to the abstract.
Read more at Cosmetic Surgery Times >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • FDA Warning Letter Signals Increased Scrutiny of the Medical Necessity Exception for Compounded GLP-1s
    • Allergan Aesthetics Debuts AA Signature in the United States with SKIN360
    • Candela Becomes Platinum Vendor Affiliate with the American Med Spa Association
    • FDA Approves Additional Warning for Kybella Labeling
    • Federal Bill Would Establish New Ownership and Management Requirements for Medical Practices
Advertisement